Dark

MYNZ
Mainz Biomed N.V.
stock NASDAQ

At Close

Dec 24, 2025 11:26:17 AM EST

1.14USD-0.870%(-0.01)86,165

1.17Bid 1.19Ask 0.02Spread

Pre-market

Dec 23, 2025 8:47:30 AM EST

1.12USD-2.591%(-0.03)0

After-hours

Dec 23, 2025 4:00:30 PM EST

1.17USD+3.540%(+0.04)0

OverviewHistoricalExchangesShortsNews

Jan 28, 2022

04:05PM EST Mainz Biomed Announces the Closing of its $25.8 Million Public GlobeNewswire Inc

Jan 27, 2022

05:01AM EST 41 Biggest Movers From Yesterday Benzinga

03:01AM EST Mainz Biomed N.V. (NASDAQ:MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Steve Quinn as Vice President of Business Development. GlobeNewswire Inc

Jan 26, 2022

02:33PM EST Mid-Afternoon Market Update: Nasdaq Surges Over 300 Points; Fed Leaves Rates Unchanged Benzinga

12:35PM EST Mid-Afternoon Market Update: Nasdaq Surges Over 300 Points; Cortexyme Shares Plummet Benzinga

12:12PM EST Mid-Day Market Update: Gold Down 1%; Corning Shares Gain On Upbeat Earnings Benzinga

10:54AM EST Shares of Mainz Biomed B.V. (MYNZ) tanked over 25% on Wednesday morning. The company announced that it priced a follow-on offering at $15 per share. RTTNews

10:28AM EST Mid-Morning Market Update: Markets Open Higher; AT&T Earnings Top Expectations Benzinga

05:53AM EST Mainz Biomed Priced 1.5M Share Follow-on Offering @$15/Share Benzinga

Jan 19, 2022

05:33AM EST Mainz Biomed Engaged DCN Dx to Support Clinical Study Evaluating Novel mRNA Biomarkers for Potential Integration into ColoAlert Benzinga

03:01AM EST Results of European study potentially incorporated into U.S. regulatory strategy for FDA approval GlobeNewswire Inc

Jan 18, 2022

02:33PM EST Mid-Afternoon Market Update: Dow Dips 500 Points; NeuroMetrix Shares Spike Higher Benzinga

10:28AM EST Shares of Mainz Biomed B.V. (MYNZ) are gaining over 22% on Tuesday morning, as the molecular genetics diagnostic company continues its rally. RTTNews

Jan 12, 2022

03:01AM EST Mainz Biomed N.V. (NASDAQ:MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Michele Pedrocchi to its Strategic Advisory Board. GlobeNewswire Inc

Jan 11, 2022

03:01AM EST Mainz Biomed N.V. (NASDAQ:MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Guido Baechler, Chief Executive Officer, will present at the H.C. Wainwright Bioconnect Virtual Conference taking place on January 10-13, 2022. GlobeNewswire Inc

Jan 6, 2022

10:10AM EST Shares of molecular genetics diagnostic company Mainz Biomed B.V. (MYNZ) are down 5 percent on Thursday's trading, thus breaking the stock's upward movement since Wednesday after the company announced that it had acquired exclusive rights to novel mRNA biomarkers. RTTNews

Jan 5, 2022

02:30PM EST Mid-Afternoon Market Update: Nasdaq Down 300 Points; Annexon Shares Plunge Benzinga

12:05PM EST Mid-Day Market Update: Nasdaq Tumbles Over 100 Points; Mainz Biomed Shares Climb Benzinga

11:50AM EST Shares of Mainz Biomed B.V. (MYNZ) surged over 40% on Wednesday morning after the molecular genetics diagnostic company announced that it acquired exclusive rights to novel mRNA biomarkers. RTTNews

10:13AM EST Mid-Morning Market Update: Markets Edge Lower; RPM International Posts Mixed Q2 Results Benzinga

07:14AM EST Mainz Biomed Shares Soar 85% Premarket After Co Announced it Acquired Exclusive Rights to Novel mRNA Biomarkers for At-home Screening Test for Colorectal Cancer Benzinga

07:13AM EST Mainz Biomed Shares Soar 85% Premarket After Co Announced itAcquired Exclusive Rights to Novel mRNA Biomarkers; Said Potential for At-home Screening Test for Colorectal Cancer Benzinga

05:43AM EST Mainz Biomed Acquired Exclusive Rights to Novel mRNA Biomarkers; Said Potential for ColoAlert to Emerge as the Most Robust and Accurate At-home Screening Test for Colorectal Cancer Benzinga

03:01AM EST Potential for ColoAlert to Emerge as the Most Robust and Accurate At-home Screening Test for Colorectal Cancer GlobeNewswire Inc

Dec 21, 2021

03:01AM EST Mainz Biomed N.V. (NASDAQ:MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Karen Richards as its Vice President of Regulatory Affairs. GlobeNewswire Inc

Dec 14, 2021

03:01AM EST -- Mainz to co-brand ColoAlert with GANZIMMUN Diagnostics, one of the largest stool analysis labs in Germany -- GANZIMMUN Diagnostics has an interdisciplinary team of over 370 medical technical assistants, physicians, chemists, biologists, and nutritionists who process approximately 5,500 laboratory orders daily GlobeNewswire Inc

Dec 7, 2021

03:01AM EST Mainz Biomed Launches Ecommerce Store for ColoAlert to Assist GlobeNewswire Inc

Nov 30, 2021

03:01AM EST Mainz Biomed Establishes Partnership with Precision for Medicine GlobeNewswire Inc

Nov 28, 2021

09:43AM EST The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week Benzinga

Nov 18, 2021

03:01AM EST -- Former Danaher executive provides significant clinical, global market, and product development expertise in cancer diagnostics GlobeNewswire Inc

Nov 15, 2021

03:01AM EST Mainz Biomed to Exhibit ColoAlert at MEDICA 2021, the GlobeNewswire Inc

Nov 11, 2021

03:01AM EST -- Former President and CEO of Roche Molecular Systems and Member of Roche's Global Diagnostic Executive Committee GlobeNewswire Inc

Nov 8, 2021

01:45PM EST Mainz Biomed N.V. (NASDAQ:MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the underwriters have exercised their over-allotment option resulting in the issuance of an additional 300,000 shares. GlobeNewswire Inc

03:01AM EST -- Flagship product ColoAlert provides a unique, life-saving early detection test for colorectal cancer -- European registration completed and commercial rollout underway across multiple territories -- FDA clinical study process to be launched for U.S. regulatory approval GlobeNewswire Inc

Nov 5, 2021

04:23PM EDT Mainz Biomed N.V. (NASDAQ:MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostics company specializing in the early detection of cancer, today announced that its common stock commenced trading on the Nasdaq Capital Market today under the ticker symbol MYNZ. The shares closed abovethe offering price at $9.99. GlobeNewswire Inc

02:57PM EDT Mid-Afternoon Market Update: Dow Surges 200 Points; Grid Dynamics Shares Spike Higher Benzinga

12:35PM EDT Mid-Day Market Update: Gold Rises 1%; Deciphera Pharmaceuticals Shares Plummet Benzinga

11:54AM EDT Mainz Biomed N.V. (Nasdaq:MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostics company specializing in the early detection of cancer, announces that its shares have commenced trading today on the Nasdaq Capital Market under the ticker symbol MYNZ. GlobeNewswire Inc

10:19AM EDT Mid-Morning Market Update: Markets Open Higher; US Economy Adds 531,000 Jobs Benzinga

10:00AM EDT Mainz Biomed B.V Shares Open For Trade At $14.35 Benzinga

09:53AM EDT Mainz Biomed B.V Shares Opened For Quote At 9:50 a.m. EDT, Expected To Open For Trade After 10 a.m. EDT Benzinga

09:43AM EDT The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill Benzinga

Nov 4, 2021

12:00PM EDT Hearing Mainz Biomed IPO Has Postponed Until Friday Benzinga

09:33AM EDT Mainz Biomed Shares Will Open For Quote At 11:50 a.m. EDT, Expected To Open For Trade After 12 p.m. EDT Benzinga

.dark-mode .n7jQXf{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .n7jQXf{ color: #333333; background-color: white; border: 2px solid #333333; }MYNZMainz Biomed N.V.stock NASDAQ

MYNZ
Mainz Biomed N.V.
stock NASDAQ